Stock Price & Analysis

Based on the analysis of GSK's recent developments and market trends, now is a favorable time to buy GSK stock as positive FDA reviews and upcoming CDC meetings may drive growth. The stock shows moderate technical indicators and potential upside from recent product advancements.

Price Prediction for GSK Stock in 2025

GSK stock is expected to reach a price target of $42 per share by the end of 2025.

• Reason 1: Strong fundamentals, including a $2.5 billion share buyback program and increased R&D investment in high-growth areas like HIV and Respiratory drugs.
• Reason 2: Positive analyst sentiment, with JPMorgan raising its price target to 1,500 GBp, reflecting confidence in GSK's long-term growth.

The S1 support level for GSK Stock is $37.93 ,The R1 resistant level for GSK Stock is $39.55.

As of the end of day on 2025-04-01, the price of GSK Stock was $37.85.

The target price for GSK Stock according to analyst rating is 42.50, with the highest price target at 45.00 and the lowest at 40.00. Analysts have a Hold rating on GSK Stock overall.

The market cap of GSK is $156.3B.

GSK appears overvalued based on its current valuation metrics. Its price-to-earnings (P/E) ratio of 21.29 and EV/EBITDA of 7.01 are higher than industry averages, suggesting elevated valuations. The price-to-sales (P/S) ratio of 1.74 and price-to-book (P/B) ratio of 4.10 further indicate premium pricing. However, its dividend yield of 4.61% provides some support. Overall, GSK's valuation metrics suggest it may be overvalued compared to industry standards.

GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.

GSK stock is predicted to reach $55 by 2030, driven by its strong pipeline of specialty medicines and increased R&D investment. The company's raised long-term sales forecast to over $50 billion by 2031 and a $2.5 billion share buyback program further support this outlook. Analysts have also raised their price targets, reflecting confidence in GSK's growth potential.

GSK has a total of 70212 employees.